AB
ABEO.US Abeona Therapeutics Inc
- Market cap
- USD 133M
- P/E
- -
- P/B
- 1.12x
- ROE
- -44.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ABEO.US undervalued?
Graham numberThe Graham number of Abeona Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abeona Therapeutics Inc fundamental analysis
No fundamental analysis for Abeona Therapeutics Inc yet.
Abeona Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition,…
Full company profileAbeona Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abeona Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 889K | 837K | 3.00M | 0.00 | 10.0M | 3.00M | 1.41M | 3.50M | 0.00 | 5.82M | 44.8M |
| Gross Profit | -9.77M | -16.2M | -35.7M | -48.6M | 10.0M | 3.00M | 964K | 1.90M | -2.91M | 4.29M | 26.8M |
| Operating Income | -23.9M | -27.8M | -58.2M | -77.1M | -81.4M | -89.8M | -50.9M | -47.1M | -64.2M | -89.4M | -66.2M |
| EBITDA | -21.0M | -26.6M | -54.3M | -68.4M | -74.5M | -76.8M | -34.4M | -50.6M | -56.6M | 78.6M | -49.9M |
| Net Income | -21.9M | -27.3M | -56.7M | -76.3M | -84.2M | -84.9M | -39.7M | -54.2M | -63.7M | 71.2M | -56.1M |
| EPS | -16 | -16 | -30 | -38 | -23 | -22 | -5.05 | -2.53 | -1.55 | 1.08 | -0.97 |
| Balance Sheet | |||||||||||
| Total Assets | 111M | 179M | 174M | 223M | 151M | 79.6M | 64.2M | 64.0M | 109M | 220M | 172M |
| Total Liabilities | 12.0M | 8.67M | 40.4M | 45.0M | 48.6M | 37.2M | 37.5M | 49.2M | 64.9M | 60.4M | 46.0M |
| Shareholders' Equity | 99.1M | 170M | 134M | 178M | 103M | 42.4M | 26.8M | 14.8M | 44.0M | 159M | 126M |
| Cash & Short-term Investments | 69.1M | 138M | 85.0M | 129M | 95.0M | 45.0M | 52.1M | 52.2M | 97.7M | 191M | 135M |
| Total Debt | - | - | 30.0M | 7.95M | 8.73M | 9.38M | 7.63M | 5.40M | 23.0M | 25.0M | 16.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.0M | -22.9M | -39.1M | -62.8M | -35.0M | -65.7M | -43.5M | -37.0M | -56.0M | -76.3M | -60.8M |
| Capital Expenditure | 519K | 860K | 19.5M | 6.51M | 1.34M | 4.15M | 130K | 331K | 2.45M | 7.98M | 2.18M |
| Free Cash Flow | -13.5M | -23.8M | -58.6M | -69.3M | -36.4M | -69.8M | -43.6M | -37.3M | -58.5M | -84.3M | -63.0M |
| Ratios | |||||||||||
| ROE | -22.1% | -16.1% | -42.3% | -42.8% | -82.1% | -200.5% | -148.3% | -365.5% | -144.7% | 44.7% | -44.6% |
| ROA | -19.7% | -15.3% | -32.5% | -34.1% | -55.7% | -106.7% | -61.8% | -84.7% | -58.5% | 32.4% | -32.6% |
| Net Profit Margin | -2,460.4% | -3,263.9% | -1,890.3% | - | -842.3% | -2,831.2% | -2,807.4% | -1,548.2% | - | 1,223.1% | -125.3% |
| Debt to Equity | - | - | 0.22x | 0.04x | 0.09x | 0.22x | 0.29x | 0.36x | 0.52x | 0.16x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Abeona Therapeutics Inc dividends
Abeona Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Jul 5, 2022.
Who owns Abeona Therapeutics Inc
- Insiders 12.30%
- Institutions 72.52%
- Public & others 15.18%
- Shares outstanding 61.6M
- Free float 36.1M
Top funds holding ABEO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.53M | 2.67% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.16M | 2.03% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 479K | 0.84% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 436K | 0.76% | 0.00% | Oct 2026 |
| Simplify Propel Opportunities ETF | 276K | 0.48% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 267K | 0.47% | +6.18% | Sep 2026 |
| Fidelity Extended Market Index | 238K | 0.42% | -12.60% | Sep 2026 |
| iShares Micro-Cap ETF | 138K | 0.24% | 0.00% | Oct 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 120K | 0.21% | +0.02% | Oct 2026 |
| Northern Small Cap Value | 116K | 0.20% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 112K | 0.20% | +6.54% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 108K | 0.19% | -6.50% | Sep 2026 |
| Fidelity Total Market Index | 98.5K | 0.17% | -0.05% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 96.0K | 0.17% | +193.15% | Aug 2026 |
| WisdomTree US SmallCap Earnings ETF | 93.2K | 0.16% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 85.8K | 0.15% | +13.45% | Sep 2026 |
| Fidelity Series Total Market Index | 84.6K | 0.15% | 0.00% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 76.5K | 0.13% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 75.0K | 0.13% | +0.33% | Oct 2026 |
Top institutions holding ABEO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 10.3M | 17.96% | +104.92% | Jun 2026 |
| BlackRock Inc | 3.35M | 5.86% | +4.91% | Jun 2026 |
| Cable Car Capital LLC | 3.01M | 5.26% | 0.00% | Jun 2026 |
| AIGH Capital Management, LLC | 2.99M | 5.22% | -3.65% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.21M | 3.87% | +2.15% | Jun 2026 |
| Resources Investment Advisors Inc | 1.65M | 2.89% | 0.00% | Jun 2026 |
| Awm Investment Company Inc | 1.49M | 2.60% | +85.04% | Jun 2026 |
| Geode Capital Management, LLC | 1.26M | 2.21% | +4.24% | Jun 2026 |
| Kennedy Capital Management Inc | 1.24M | 2.17% | -1.86% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.22M | 2.14% | +8.33% | Jun 2026 |
| State Street Corp | 1.04M | 1.82% | +8.66% | Jun 2026 |
| Propel Bio Management LLC | 983K | 1.72% | -26.08% | Jun 2026 |
| Diametric Capital, LP | 755K | 1.32% | +23.47% | Jun 2026 |
| J. Goldman & Co LP | 678K | 1.19% | +5.88% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 610K | 1.07% | -5.94% | Jun 2026 |
| Rubric Capital Management LP | 609K | 1.06% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 557K | 0.97% | -25.36% | Jun 2026 |
| Northern Trust Corp | 553K | 0.97% | +26.76% | Jun 2026 |
| NAN FUNG TRINITY (HK) Ltd | 552K | 0.97% | -42.28% | Sep 2026 |
| Citigroup Inc | 548K | 0.96% | +4.95% | Jun 2026 |
Abeona Therapeutics Inc company profile
- Company name
- Abeona Therapeutics Inc
- Ticker
- ABEO.US
- Exchange
- USA Stocks
- Listed since
- Sep 19, 1980
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 226
- Fiscal year end
- December
- Address
- 6555 Carnegie Avenue, Cleveland, OH, United States, 44103
- Phone
- 646 813 4701
- Website
- abeonatherapeutics.com
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Abeona Therapeutics Inc management
10- Dr. Vishwas Seshadri M.B.A., Ph.D.President, CEO & Director · born 1976
- Mr. Joseph Walter Vazzano CPAChief Financial Officer · born 1984
- Dr. Brendan M. O'Malley J.D., Ph.D.Chief Legal Officer · born 1969
- Mr. Brian Kevany Ph.D.Chief Technical & Scientific Officer
- Mr. Gregory GinVice President of Investor Relations & Corporate Communications
- Ms. Gianine EspositoSenior VP & Chief People Officer
- Mr. Jon VossVP & Head of Quality · born 1960
- Dr. Madhav Vasanthavada M.B.A., Ph.D.SVP, Chief Commercial Officer & Head of Business Development · born 1979
- Mr. Carl DennySenior Vice President of Regulatory Affairs
- Ms. Megan CallanVice President & Head of Quality